Companies: 10,795·Total market cap: $144.5T
KalVista Pharmaceuticals, Inc.

KalVista Pharmaceuticals, Inc.

KALVNASDAQHealthcare● Active
$26.95
+$0.00(+0.00%)
Market Cap$1.4B
P/E Ratio
52W High$26.98
52W Low$9.83
SEC Filings

KalVista Pharmaceuticals, Inc. (KALV) SEC Filings & 10-K Annual Reports

SEC EDGAR regulatory submissions (10-K, 10-Q, 8-K), latest forms, and full filing history — quick links to financials and earnings below.

SEC EDGAR · data.sec.gov · CIK 0001348911 · KALV · NASDAQ · as of Jun 8, 2026

Filing snapshot

843
Total Filings
SC TO-T/A
Latest Form
2026-06-01
Most Recent
2015
Filing Since

Source: SEC EDGAR (data.sec.gov) · CIK 0001348911 · Updated hourly · Not investment advice

Latest Annual Report

10-K · Annual ReportFY
Filed Date
2026-04-30
Fiscal Year End
Apr 30, 2026
Accession No.
0001193125-26-197556
Primary Document
d121999d10kta.htm
Source: data.sec.gov · CIK 0001348911 · Accession 0001193125-26-197556

Latest Key Filings

10-QQuarterly Report
10-Q
2026-05-14
8-KCurrent Report
8-K
2026-04-29Material Event
Form 4Insider Activity
Ownership Change Disclosures

Executive & director trade disclosures. Full buy/sell sentiment analysis on the dedicated tab.

SEC Filing History

Hide Form 4 / 144
SC TO-T/ASC TO-T/A
SC TO-T/A
2026-06-01
View
SC 14D9/ASC 14D9/A
SC 14D9/A
2026-06-01
View
SCHEDULE 13D/ASCHEDULE 13D/A
SCHEDULE 13D/A
2026-05-21
View
SCHEDULE 13G/ASCHEDULE 13G/A
SCHEDULE 13G/A
2026-05-15
View
10-QQuarterly Report
10-Q
2026-05-14
View
SC 14D9SC 14D9
SC 14D9
2026-05-13
View
SCHEDULE 13GSCHEDULE 13G
SCHEDULE 13G
2026-05-13
View
SC TO-TSC TO-T
SC TO-T
2026-05-13
View
SC TO-CSC TO-C
SC TO-C
2026-05-05
View
SCHEDULE 13G/ASCHEDULE 13G/A
SCHEDULE 13G/A
2026-05-01
View
10-KT/A10-KT/A
10-KT/A
2026-04-30
View
SC14D9CSC14D9C
SC14D9C
2026-04-29
View
8-KCurrent Report
8-K
2026-04-29
View
10-KT10-KT
10-KT
2026-03-25
View
8-KCurrent Report
8-K
2026-03-25
View
Showing 1–15 of 451 filingsForm 4 / 144 hidden· 843 total in EDGAR

About SEC Filings & 10-K Annual Reports

Data source: SEC EDGAR (data.sec.gov)  |  Updated: Hourly  |  CIK: 0001348911  |  Exchange: NASDAQ · Healthcare

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) has submitted 843 documents to the U.S. Securities and Exchange Commission (SEC) since its IPO in 2015. As a Healthcare sector company with CIK 0001348911, all filings are publicly accessible via the EDGAR database at no cost.

The annual 10-K report is KalVista Pharmaceuticals, Inc.'s most comprehensive regulatory disclosure. The most recent KalVista Pharmaceuticals, Inc. 10-K was filed on 2026-04-30 for fiscal year ending 2026. Historical KALV 10-K annual reports are available from 2005 through 2026.

Investors researching KalVista Pharmaceuticals, Inc. SEC filings can access 10-K annual reports, quarterly 10-Q reports, material event 8-K filings, and proxy statements directly from the links above. All documents are sourced from the official SEC EDGAR system.

Source: SEC EDGAR · data.sec.gov · SEC Form 10-K · SEC Form 10-Q · SEC Form 8-K2026-06-08

Frequently Asked Questions

KALV SEC Filings · 8 questions

KalVista Pharmaceuticals, Inc. (KALV) SEC filings are publicly available on this page and on the official SEC EDGAR database at sec.gov. You can browse all 843 filings and access original documents at no cost. KalVista Pharmaceuticals, Inc.'s CIK is 0001348911.

KALV SEC filingsKalVista Pharmaceuticals, Inc. SEC documentsfind KALV 10-K